Skip to main content
4
New Upcoming Webinar:
Optimizing Therapeutic Drug Monitoring: Practical Knowledge and Lessons
Tuesday, February 4, 2025
4
Health Canada Approves
Saladax’s 5-Fluorouracil
Chemotherapy Therapeutic
Drug Monitoring Test

Our Mission

At Saladax, we develop and manufacture therapeutic drug monitoring (TDM) assays
for essential and life-saving medications prescribed by psychiatrists and oncologists. These assays ensure that each and every patient receives their optimal dose.

General News
February 18, 2025

Saladax Biomedical Inc. Appoints Regulatory and Quality Expert Ms. Stacie Geffner-Atiya as Director of Regulatory and Quality

Bethlehem, PA – February 18, 2025 – Saladax Biomedical, Inc., a leader in innovative therapeutic drug monitoring (TDM) solutions, is pleased to announce the appointment of Ms. Stacie Geffner-Atiya as…
General News
November 21, 2024

Saladax Biomedical Inc. Welcomes Dr. Sepideh Fanaei as Country Manager for DACH Region, Supporting EU Expansion and Revenue Growth

Bethlehem, PA – November 21, 2024 – Saladax Biomedical, Inc. is thrilled to announce the appointment of Dr. Sepideh Fanaei as Country Manager for the DACH region, which encompasses Germany,…
Oncology News
June 5, 2024

Health Canada Approves Saladax’s 5-Fluorouracil Chemotherapy Therapeutic Drug Monitoring (TDM) Test

Bethlehem, PA – May 14, 2024 – Saladax Biomedical, Inc. (Saladax) is pleased to announce that Health Canada has approved Saladax’s 5-Fluorouracil (My5-FU) Assay for sale in Canada in a…
Psychiatry News
July 24, 2023

Determining Clozapine Response vs. Nonresponse

Determining Clozapine Response vs. Nonresponse Recorded in July 2023 at Saladax’s first Virtual Product Theater in conjunction with AAPP Description: When treating patients with clozapine, it is essential to distinguish…

Request Information

Please fill out the form and we will contact you.


This will close in 20 seconds

This will close in 20 seconds